We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+6.98%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$368M
AUM Growth
+$18.7M
Cap. Flow
+$14.9M
Cap. Flow %
4.04%
Top 10 Hldgs %
6.4%
Holding
553
New
113
Increased
199
Reduced
149
Closed
92

Top Buys

Rank Stock Value
1
EXPD icon
Expeditors International
EXPD
+$2.17M
2
INCY icon
Incyte
INCY
+$2.09M
3
WAT icon
Waters Corp
WAT
+$2.03M
4
AMAT icon
Applied Materials
AMAT
+$2.01M
5
LVS icon
Las Vegas Sands
LVS
+$2.01M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$2.5M
2
EA
Electronic Arts
EA
+$2.43M
3
FOXA icon
Fox Class A
FOXA
+$2.05M
4
MS icon
Morgan Stanley
MS
+$2.04M
5
ATO icon
Atmos Energy
ATO
+$2.02M

Sector Composition

Rank Sector Weight
1 Healthcare 26.73%
2 Financials 22.73%
3 Technology 18.16%
4 Industrials 8.89%
5 Consumer Discretionary 7.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KROS icon
326
Keros Therapeutics
KROS
$216M
$252K 0.07%
12,367
+4,025
+48% +$70.6K
ABCL icon
327
AbCellera Biologics
ABCL
$2.9B
$251K 0.07%
73,488
+37,365
+103% +$167K
RXRX icon
328
Recursion Pharmaceuticals
RXRX
$1.78B
$251K 0.07%
61,439
+39,430
+179% +$195K
CNTA
329
DELISTED
Centessa Pharmaceuticals
CNTA
$251K 0.07%
10,034
+583
+6% +$14.8K
ARVN icon
330
Arvinas
ARVN
$585M
$251K 0.07%
21,148
+6,117
+41% +$66.8K
ASMB icon
331
Assembly Biosciences
ASMB
$525M
$251K 0.07%
+7,369
New +$237K
NAMS icon
332
NewAmsterdam Pharma
NAMS
$3.32B
$251K 0.07%
7,142
+1,731
+32% +$63K
IRWD icon
333
Ironwood Pharmaceuticals
IRWD
$696M
$250K 0.07%
+74,311
New +$193K
SRRK icon
334
Scholar Rock
SRRK
$6.26B
$250K 0.07%
5,676
+2,261
+66% +$84.8K
XNCR icon
335
Xencor
XNCR
$1.56B
$247K 0.07%
16,103
+4,037
+33% +$60.3K
AMLX icon
336
Amylyx Pharmaceuticals
AMLX
$2.49B
$245K 0.07%
+20,307
New +$276K
PRTA icon
337
Prothena Corp
PRTA
$441M
$245K 0.07%
25,679
+3,236
+14% +$32.9K
RAPT
338
DELISTED
RAPT Therapeutics
RAPT
$245K 0.07%
+7,229
New +$225K
CRVS icon
339
Corvus Pharmaceuticals
CRVS
$1.13B
$245K 0.07%
31,783
+4,946
+18% +$39K
DNLI icon
340
Denali Therapeutics
DNLI
$3.92B
$244K 0.07%
14,795
+7,171
+94% +$121K
PTGX icon
341
Protagonist Therapeutics
PTGX
$9.63B
$244K 0.07%
2,790
+770
+38% +$63K
ELVN icon
342
Enliven Therapeutics
ELVN
$4.38B
$243K 0.07%
15,778
+9,991
+173% +$199K
BCAX
343
Bicara Therapeutics
BCAX
$1.84B
$242K 0.07%
14,395
+4,560
+46% +$77.9K
ALLO icon
344
Allogene Therapeutics
ALLO
$704M
$241K 0.07%
176,178
+94,902
+117% +$125K
ACLX
345
DELISTED
Arcellx
ACLX
$241K 0.07%
3,701
+1,990
+116% +$159K
JANX icon
346
Janux Therapeutics
JANX
$982M
$240K 0.07%
17,388
+12,936
+291% +$304K
VIR icon
347
Vir Biotechnology
VIR
$1.5B
$240K 0.07%
39,764
+17,966
+82% +$107K
TERN
348
DELISTED
Terns Pharmaceuticals
TERN
$239K 0.06%
5,912
-23,041
-80% -$532K
ZBIO
349
Zenas BioPharma
ZBIO
$2.04B
$238K 0.06%
+6,554
New +$216K
MGTX icon
350
MeiraGTx Holdings
MGTX
$1.21B
$237K 0.06%
+29,824
New +$248K
12 13
14
15 16

Similar funds

RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

Virtus Investment Advisers's Q4 2025 Portfolio in Review

As of Q4 2025, Virtus Investment Advisers held 553 positions worth $368M, up 5.3% from $349M the previous quarter. Its ten largest holdings account for 6.4% of the portfolio.

Virtus Investment Advisers deployed $14.9M of net new capital in Q4 2025, opening 113 new positions and adding to 199 existing holdings. Its largest new stake was Expeditors International: 15,974 shares worth $2.38M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 17% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was VICI Properties, an estimated $1.66M trimmed.

  • Virtus Investment Advisers's largest Q4 2025 buy was Expeditors International: 15,974 shares worth $2.38M.
  • Virtus Investment Advisers added most to Incyte in Q4 2025, an estimated $2.09M increase.
  • Virtus Investment Advisers's biggest Q4 2025 reduction was VICI Properties, cutting an estimated $1.66M.
  • Virtus Investment Advisers fully exited Tesla in Q4 2025, selling an estimated $2.5M.
  • Virtus Investment Advisers's ten largest holdings make up 6.4% of its $368M portfolio in Q4 2025.
  • Virtus Investment Advisers opened 113 new positions and closed 92 in Q4 2025.
  • Virtus Investment Advisers's portfolio value rose 5.3% quarter-over-quarter to $368M.

Based on Virtus Investment Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.